University of California

Lucky Biotech Corporation

Other

Chiron Corporation

Lucky Limited

Sung-Hou Kim

Joong M Cho

Peter G Schultz

Laurent Meijer

Nathanael S Gray

Rosalind Kim

Kirston E Koths

Robert F Halenbeck

Robert L Fischer

Eric W Taylor

James Giovannoni

Lola Penarrubia

Anna Lisa Fear

Jarmila Jancarik

Jayvardhan Pandit

Ralph Yamamoto

Andrew Bohm

Jamila Jancarik

An optimum solubility screen in which a panel of buffers and many additives are provided in order to obtain the most homogeneous and monodisperse protein condition for protein crystallization. The present methods are useful for proteins that aggregate and cannot be concentrated prior to setting up crystallization screens. A high-throughput method using the hanging-drop method and vapor diffusion equilibrium and a panel of twenty-four buffers is further provided. Using the present methods, 14 poorly behaving proteins have been screened, resulting in 11 of the proteins having highly improved dynamic light scattering results allowing concentration of the proteins, and 9 were crystallized.

High-throughput method for optimum solubility screening for homogeneity and crystallization of proteins

The present invention relates to 2-N-substituted 6-(4-methoxybenzylamino)-9-isopropylpurines that inhibit, inter alia, protein kinases, G-proteins and polymerases. In addition, the present invention relates to methods of using such 2-N-substituted 6-(4-methoxybenzylamino)-9-isopropylpurines to inhibit protein kinases, G-proteins, polymerases and other cellular processes and to treat cellular proliferative diseases.

Purine inhibitors of protein kinases, G proteins and polymerases

The present invention relates to purine analogs that inhibit, inter alia, protein kinases, G-proteins and polymerases. In addition, the present invention relates to methods of using such purine analogs to inhibit protein kinases, G-proteins, polymerases and other cellular processes and to treat cellular proliferative diseases.

The present invention is directed to methods for crystallizing macrophage colony stimulating factor. The present invention is also directed to methods for designing and producing M-CSF agonists and antagonists using information derived from the crystallographic structure of M-CSF. The invention is also directed to methods for screening M-CSF agonists and antagonists. In addition, the present invention is directed to an isolated, purified, soluble and functional M-CSF receptor.

Identification of M-CSF agonists and antagonists

Crystallization of M-CSF.alpha.

Edible fruit, seed and vegetables of transgenic plants modified to produce a sweetening protein such as monellin or thaumatin are useful in preparing food compositions which have enhanced sweetness improved flavor. Expression systems for the genes encoding sweetening proteins compatible with plant systems and designed to enhance the production of these proteins in the edible portions of plants, and methods for producing sweetened fruit, seeds and vegetables are described.

Endogenously sweetened transgenic plant products

Single-chain analogs of the naturally occurring two-chain peptide monellin retain the sweetening properties of the natural protein and are stable under conditions which would otherwise destabilize the native peptide. A covalent linkage joins peptides corresponding to portions of the A and B chains of the naturally occurring protein.

Growing community of inventors

Moraga, CA, United States of America

Sung-Hou Kim